Journal
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
Volume 12, Issue 5, Pages 492-501Publisher
SPRINGER
DOI: 10.1007/s11910-012-0290-7
Keywords
Parkinson's disease; Dementia; Dementia with Lewy bodies; Rivastigmine; Memantine; Cholinesterase inhibitors
Categories
Funding
- Lundbeck
- Novartis
- GSK
- Esai pharmaceutical company
- Bristol-Myers Squibb pharmaceutical company
- Janssen pharmaceutical company
- Acadia pharmaceutical company
- Novartis pharmaceutical company
- Lundbeck pharmaceutical company
Ask authors/readers for more resources
Despite the frequency and importance of dementia associated with Parkinson's disease (PDD) and dementia with Lewy bodies (DLB), there is relatively little evidence on which to base treatment. Evidence from meta-analysis suggests that rivastigmine can improve cognition and functioning in PDD and also reduce risk of falling. There is also evidence supporting its use in DLB. Recent evidence suggests that memantine may also be effective, particularly for PDD, although evidence is more conflicting. Memantine may also improve parkinsonism and dyskinesias. Few clinical trials of cognition in PD without dementia exist, but there is preliminary evidence for atomoxetine, memantine, and piribedil. There is a lack of systematic evidence for the treatment of visual hallucinations and depression in PDD and DLB. In addition, there is a need for studies of whether potentially disease-modifying agents can prevent or delay the progression to dementia in PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available